- Language: English
- 139 Pages
- Published: October 2011
- Region: Global
Global MicroRNA Market 2012-2016
- Published: September 2013
- Region: Global
- 56 pages
The analysts forecast the Global MicroRNA market to grow at a CAGR of 17.51 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increase in microRNA research funding. The Global MicroRNA market has also been witnessing the discovery and development of microRNAs as biomarkers for diseases. However, the high R&D costs could pose a challenge to the growth of this market.
The report, Global MicroRNA Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers North America, Europe, and the ROW; it also covers the Global MicroRNA market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
The key vendors dominating this market space are Alnylam Pharmaceuticals Inc., Exiqon A/S, and Santaris Pharma A/S.
Other vendors mentioned in the report are Access Pharmaceuticals, Aegera Therapeutics Inc., Affymetrix Inc., Agilent Technologies, Antisense Pharma GmbH, Aparna Biosciences Corp., Applied Biological Materials Inc., Arrowhead Research Corp., AstraZeneca Pharmaceuticals LP, Asuragen Inc., Benitec Biopharma Ltd., BioCancell Therapeutics Inc., Biogen Idec Inc., CBC Comprehensive Biomarker Center GmbH, Clontech Laboratories Inc., Dicerna Pharmaceuticals Inc., Eli Lilly and Co., EMD4Biosciences, Expression Genetics Inc., F. Hoffman-La Roche AG, Fluidigm Corp., GeneCopoeia Inc., GenoSensor Corp., Gensignia Inc., Groove Biopharma, GlaxoSmithKline, HTG Molecular Diagnostics Inc., Idera Pharmaceuticals Inc., Illumina Inc., InteRNA Technologies B.V., Isis Pharmaceuticals Inc., LC Sciences Llc, Life Technologies Corp., Merck & Co. Inc., miRagen Therapeutics Inc., Mirna Therapeutics Inc., NanoString Technologies Inc., Norgen Biotek Corp., Novartis AG, Pfizer Inc., Phalanx Biotech Group, PhaseRx Inc., Prolias Technologies Inc., Qiagen N.V., Quark Pharmaceuticals Inc., Regulus Therapeutics Inc., Rosetta Genomics Ltd., RXi Pharmaceuticals Corp., Sanofi U.S., Sarepta Therapeutics, Sigma-Aldrich Co. Llc, Silence Therapeutics Plc, Sirnaomics Inc., siRNAsense AS, Sylentis SA, Tacere Therapeutics Inc., Tekmira Pharmaceuticals Corp., Theradiag, Thermo Fisher Scientific Inc., and WaferGen Biosystems Inc.
Key questions answered in this report:
- What will the market size be in 2016 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report. SHOW LESS READ MORE >
01. Executive Summary
02. Scope of the Report
02.1 Market Overview
02.2 Product Offerings
03. Market Research Methodology
03.1 Market Research Process
03.2 Research Design
03.3 Research Methodology
04. List of Abbreviations
06. Market Landscape
06.1 Market Overview
07. Global MicroRNA Research Market
08. Global MicroRNA Market
08.1 Market Size and Forecast
08.2 Five Forces Analysis
09. Global MicroRNA Market Segmentation
09.1 Global MicroRNA Tools and Reagents Market
09.1.1 Market Size and Forecast
09.2 Global MicroRNA Therapeutics Market
09.2.1 Market Size and Forecast
09.3 Global MicroRNA Diagnostics Market
09.3.1 Market Size and Forecast
10. Geographical Segmentation
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.2 Key Vendor Ranking 2012
18.3 Other Prominent Vendors
19. Key Vendor Analysis
19.1 Alnylam Pharmaceuticals Inc.
19.1.1 Business Overview
19.1.2 Business Segmentation
19.1.3 Key Information
19.1.4 SWOT Analysis
19.2 Exiqon A/S
19.2.1 Business Overview
19.2.2 Business Segmentation
19.2.3 Key Information
19.2.4 SWOT Analysis
19.3 Santaris Pharma A/S
19.3.1 Business Overview
19.3.2 Business Segmentation
19.3.3 Key Information
19.3.4 SWOT Analysis
20. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Market Segmentation
Exhibit 3: Market Segmentation by Geography
Exhibit 4: MicroRNA Research Publications
Exhibit 5: Models Employed for MicroRNA Research
Exhibit 6: Areas with MicroRNA Research
Exhibit 7: Global MicroRNA Market 2012-2016 (US$ million)
Exhibit 8: Global MicroRNA Market Segmentation
Exhibit 9: Global MicroRNA Market Segmentation 2012
Exhibit 10: Global MicroRNA Market Segmentation 2012-2016
Exhibit 11: Global MicroRNA Tools and Reagents Market 2012-2016 (US$ million)
Exhibit 12: Global MicroRNA Expression Profiling Market Segmentation by Type of Technology
Exhibit 13: Global MicroRNA Tools and Reagents Market Segmentation by Geography
Exhibit 14: Global MicroRNA Therapeutics Market 2012-2016 (US$ million)
Exhibit 15: Global MicroRNA Diagnostics Market 2012-2016 (US$ million)
Exhibit 16: Global MicroRNA Market Segmentation by Geography 2012
Exhibit 17: Business Segmentation of Alnylam Pharmaceuticals Inc.
Exhibit 18: Business segmentation of Exiqon A/S
Exhibit 19: Business Segmentation of Santaris Pharma A/S
Commenting on the report, an analyst from the team said: “A biomarker is a substance or a molecular or cellular process or event that indicates a biological condition. Several research studies have confirmed that microRNAs have immense potential as biomarkers for a range of diseases, from cancer to cardiovascular diseases. An increasing number of vendors in the market are focusing on the discovery of microRNA biomarkers for diseases that do not as yet have defined microRNA biomarkers. For instance, Biogen Idec Inc., a US-based biotechnology company focusing on the development of drugs for the Healthcare sector, and Regulus Therapeutics Inc., a US-based microRNA therapeutics company, have collaborated in their efforts to discover and develop microRNA biomarkers for multiple sclerosis. Thus, the Global MicroRNA market is witnessing the increasing use of microRNAs as biomarkers.”
According to the report, one of the most important drivers is the increasing prevalence of diseases such as cancer, which has led to an increase in demand for microRNA-based diagnostic tests.
Further, the report states that one of the major challenges in the market is the stringent regulations imposed by the regulatory bodies. Complying with such regulations and obtaining approvals from regulatory authorities is a major challenge for the vendors in this market.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
- Alnylam Pharmaceuticals Inc.
- Exiqon A/S
- Santaris Pharma A/S.
- Access Pharmaceuticals
- Aegera Therapeutics Inc.
- Affymetrix Inc.
- Agilent Technologies
- Antisense Pharma GmbH
- Aparna Biosciences Corp.
- Applied Biological Materials Inc.
- Arrowhead Research Corp.
- AstraZeneca Pharmaceuticals LP
- Asuragen Inc.
- Benitec Biopharma Ltd.
- BioCancell Therapeutics Inc.
- Biogen Idec Inc.
- CBC Comprehensive Biomarker Center GmbH
- Clontech Laboratories Inc.
- Dicerna Pharmaceuticals Inc.
- Eli Lilly and Co.
- Expression Genetics Inc.
- F. Hoffman-La Roche AG
- Fluidigm Corp.
- GeneCopoeia Inc.
- GenoSensor Corp.
- Gensignia Inc.
- Groove Biopharma
- HTG Molecular Diagnostics Inc.
- Idera Pharmaceuticals Inc.
- Illumina Inc.
- InteRNA Technologies B.V.
- Isis Pharmaceuticals Inc.
- LC Sciences Llc
- Life Technologies Corp.
- Merck & Co. Inc.
- miRagen Therapeutics Inc.
- Mirna Therapeutics Inc.
- NanoString Technologies Inc.
- Norgen Biotek Corp.
- Novartis AG
- Pfizer Inc.
- Phalanx Biotech Group
- PhaseRx Inc.
- Prolias Technologies Inc.
- Qiagen N.V.
- Quark Pharmaceuticals Inc.
- Regulus Therapeutics Inc.
- Rosetta Genomics Ltd.
- RXi Pharmaceuticals Corp.
- Sanofi U.S.
- Sarepta Therapeutics
- Sigma-Aldrich Co. Llc
- Silence Therapeutics Plc
- Sirnaomics Inc.
- siRNAsense AS
- Sylentis SA
- Tacere Therapeutics Inc.
- Tekmira Pharmaceuticals Corp.
- Thermo Fisher Scientific Inc.
- and WaferGen Biosystems Inc.